WEBULL
WebtradeDownload

Can 4DMedical's (ASX:4DX) Rising Revenue Offset Its Deepening Net Losses?

Simply Wall St · 2d ago
  • In the past financial year ended June 30, 2026, 4DMedical Limited reported A$7.06 million in sales, up from A$5.85 million, alongside a net loss of A$204.44 million compared with A$30.07 million previously.
  • Despite the wider net loss, the company’s basic and diluted loss per share from continuing operations improved to A$0.03 from A$0.14, highlighting the effect of a larger share base on per-share metrics.
  • We will now examine how 4DMedical’s combination of higher revenue and a very large increase in net loss shapes its investment narrative.

This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

What Is 4DMedical's Investment Narrative?

For someone holding 4DMedical, the core belief is that its lung imaging software can become embedded in everyday clinical and research workflows, from CT:VQ scans in hospitals to analytics for pharma trials. The latest result, with A$7.06 million in sales but a much larger A$204.44 million loss, sharpens the focus on whether that vision can be funded and executed efficiently. Recent regulatory wins, pharma and AI partnerships, and index inclusions still look like the key short term catalysts, but the size of the loss means capital intensity and potential future dilution matter more than they did before this update. The sharp share price pullback since the announcement suggests the market is reassessing how quickly commercial traction can offset those mounting costs.

However, one risk now stands out more clearly than it did before these results. Despite retreating, 4DMedical's shares might still be trading 5% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

ASX:4DX 1-Year Stock Price Chart
ASX:4DX 1-Year Stock Price Chart
Eight Simply Wall St Community fair value views span A$0.36 to A$11.11, underlining very different expectations. Set that against the latest A$204.44 million annual loss and capital needs, and you can see why it pays to examine several of these perspectives side by side.

Explore 8 other fair value estimates on 4DMedical - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.